1. Medtech Insight
  2. >>Policy & Regulation

CMS Proposes Coverage For Colorectal Cancer Blood-Based Tests – Except For Epigenomics’ Screen

 
• By Sue Darcey

The US Medicare agency coupled its proposed coverage memo on colorectal cancer screens based on blood-based biomarker tests with a note that the Epi proColon assay does not meet its criteria.

Medicare has issued a proposed decision memo for screening for colorectal cancer

The US Centers for Medicare and Medicaid Services (CMS) has proposed that evidence is sufficient to cover a blood-based biomarker test as a colorectal cancer screening test once every three years, but added it is not proposing to cover Epigenomics’ Epi proColon assay, which did not meet the agency’s criteria for coverage.

Alternatively, blood-based biomarker tests for the cancer could be covered at intervals designated in the Food and Drug Administration label,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Zimmer Biomet Readies Iodine-Coated Hip For 2025 Japan Launch, Plans To Expand Platform To New Joint

 
• By Shubham Singh

Zimmer Biomet is preparing to introduce iodine-coated hip implants to international markets, offering joint replacement patients a new alternative intended to ward off infection. The company intends to broaden the platform’s reach into “knees, shoulders and other categories in due time.”

From Risk Aversion to Real-World Impact: How Medtech Firms Can Harness AI

 
• By Elizabeth Orr

Medical device companies are increasingly using AI to improve regulatory affairs strategies but face barriers such as risk aversion, regulatory clarity and data governance issues. Experts suggest a design control approach and human oversight to ensure successful AI integration.

Hundreds Of Adverse Events, Multiple Deaths, Associated With Abbott Correction Of Libre 3 Sensors

 
• By Brian Bossetta

Abbott has initiated a medical device correction for about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the US after internal testing detected a risk the device may produce inaccurate glucose readings.